

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Recombinant Human EphA2 (C-Fc) EBT-EPT099

Article Name	Recombinant Human EphA2 (C-Fc)
Biozol Catalog Number	EBT-EPT099
Supplier Catalog Number	EPT099
Alternative Catalog Number	EBT-EPT099-50
Manufacturer	ELK Biotechnology
Category	Proteine/Peptide
Product Description	Recombinant Human Ephrin A Receptor 2 is produced by our Mammalian expression system and the target gene encoding Ala24-Asn534 is expressed with a Fc tag at the C-terminus....
Molecular Weight	Molecular weight: 83 KDa. Apparent molecular weight: 90-120 KDa, reducing conditions
UniProt	P29317
Purity	Greater than 95% as determined by reducing SDS-PAGE.

Application Notes

Redissolve: Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.. Endotoxin: Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. Background: Ephrin type-A receptor 2/EphA2 is a member of the Eph receptor tyrosine kinase family which binds Ephrins A1, 2, 3, 4, and 5. A and B class Eph proteins have a common structural organization. Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. EphA2 becomes autophosphorylated following ligand binding and then interacts with SH2 domain-containing PI3-kinase to activate MAPK pathways. Reverse signaling is also propagated through the Ephrin ligand. Transcription of EphA2 is dependent on the expression of E-Cadherin, and can be induced by p53 family transcription factors. EphA2 is upregulated in breast, prostate, and colon cancer vascular endothelium. Its ligand, EphrinA1, is expressed by the local tumor cells. In some cases, EphA2 and EphrinA1 are expressed on the same blood vessels. EphA2 signaling cooperates with VEGF receptor signaling in promoting endothelial cell migration.